International non- proprietary name: Cetuximab

 Brand name: Erbitux

 Target; Format: Erbitux EGFR; Chimeric IgG1

Indication first approved or reviewed:  Colorectal cancer

First EU approval year: 2004

 First US approved: 2004

Testimonials

Monoclonal Antibody PPT Presentation. 8 slides. Due in 20 hours
We have updated our contact contact information. Text Us Or WhatsApp Us+1-(309) 295-6991